Company / Operating Income
Mirum Pharmaceuticals, Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$22.1M
FY2025
5-year range
-$173.4M / -$22.1M
FY2021-FY2025
Trend
+74.7%
vs FY2024
Sector context
#64 of 204
Health Care
What the data says
At -$22M, Mirum Pharmaceuticals, Inc.'s operating income ranks #64 of 204 in the Health Care sector. Operating Income has increased for 3 consecutive years, from -$173M in FY2022 to -$22M in FY2025.
Based on SEC 10-K filings.
-$22M in FY2025.
Improved from -$109M to -$22M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#64 of 204 in Health CareTop 31% of 204This company -$22.1M Sector average $107.8M
▼
-120.5% below sector average
Key checks
Key Insights
- Mirum Pharmaceuticals, Inc.'s operating income has grown for 3 consecutive years.
- In FY2025, operating income increased 74.7% year-over-year.
- Ranks #64 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -26.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$22.1M | +74.7% |
| FY2024 | -$87.6M | +19.7% |
| FY2023 | -$109.2M | +37.1% |
| FY2022 | -$173.4M | -66.3% |
| FY2021 | -$104.3M | +0.0% |
| FY2020 | -$104.3M | -90.5% |
| FY2019 | -$54.7M | -214.5% |
| FY2018 | -$17.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026